



# Proteomics International

LABORATORIES LTD

ASX Release  
6 February 2018

ASX code: PIQ

## Investor conference call Alliance with CPR Pharma and Launch of PromarkerD

Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ) is pleased to confirm that Canary Capital will be hosting a conference call with Managing Director, Dr Richard Lipscombe, on **Thursday 8th of February at 11am AEDT**.

Dr Lipscombe will discuss the significance of the recently announced strategic alliance with CPR Pharma Services (ASX: 2 Feb 2018) as well as the upcoming launch of the company's PromarkerD test (ASX: 27 Nov 2017). There will be time at the end for questions to be asked.

### Registration and dial-in details

If you would like to register for the call or submit questions please email Paul Hart at: [phart@canarycapital.com.au](mailto:phart@canarycapital.com.au)

ENDS

### For further information please contact:

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Paul Hart [Investor Relations]  
Director  
Canary Capital  
T: +61 421 051 474  
E: [phart@canarycapital.com.au](mailto:phart@canarycapital.com.au)

### About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))

Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. Proteomics International is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)